Table 1.
Baseline clinical characteristics of participants in the SOMAscan
| Characteristic | No CKD (N = 96) | CKD (N = 84) | P value |
|---|---|---|---|
| Male, N (%) | 51 (52.58) | 38 (42.70) | 0.29 |
| Duration (years) | 54.66 (5.43) | 56.26 (6.92) | 0.10 |
| Age (years) | 66.2 (7.49) | 67.35 (7.61) | 0.34 |
| Insulin dose (units/kg) | 0.46 (0.14) | 0.46 (0.19) | 0.90 |
| BMI (kg/m2) | 26.29 (4.16) | 28.22 (6.06) | 0.02 |
| HbA1c (%) | 7.63 (0.69) | 7.29 (1.02) | 0.01 |
| HbA1c (mmol/mol) | 59.92 (7.57) | 56.15 (11.10) | 0.01 |
| LDLc (mg/dL) | 84.71 (23.99) | 80.5 (27.05) | 0.32 |
| LDLc (mmol/L) | 2.19 (0.62) | 2.1 (0.7) | 0.32 |
| Total cholesterol (mg/dL) | 164.46 (32.87) | 158.38 (37.16) | 0.28 |
| Total cholesterol (mmol/L) | 4.26 (0.85) | 4.1 (0.96) | 0.28 |
| Triglycerides (mg/dL) | 68.82 (29.15) | 98.52 (52.47) | <0.001 |
| Triglycerides (mmol/L) | 0.78 (0.33) | 1.11 (0.59) | <0.001 |
| HDLc (mg/dL) | 66.25 (21.14) | 57.89 (21.29) | 0.01 |
| HDLc (mmol/L) | 1.72 (0.55) | 1.5 (0.55) | 0.01 |
| eGFR (mL/min/1.73 m2) | 76.63 (15.97) | 35.84 (7.88) | <0.001 |
| ACR (μg/mg) | 39.23 (103.90) | 208.79 (650.71) | <0.001 |
| ACR (mg/mmol) | 4.44 (11.75) | 23.62 (73.61) | <0.001 |
| Systolic blood pressure (mmHg) | 132.2 (16.95) | 132.44 (18.08) | 0.93 |
| Diastolic blood pressure (mmHg) | 62.87 (7.58) | 63.7 (9.34) | 0.53 |
| Lipid-lowering medication, N (%) | 68 (72.32) | 60 (74.07) | 0.87 |
| Hypertensive medication, N (%) | 56 (59.57) | 66 (81.48) | 0.002 |
| Detectable C-peptide, N (%) | 49 (50.52) | 27 (33.33) | 0.01 |
| CVD, N (%) | 37 (39.78) | 50 (60.98) | 0.03 |
| PDR, N (%) | 41 (52.56) | 47 (73.44) | 0.01 |
| Neuropathy, N (%) | 73 (80.22) | 54 (68.35) | 0.08 |
Data are mean (SD) for continuous variables unless otherwise noted. CKD is stage 3b, as defined by CKD-EPI eGFR <45 mL/min/1.73 m2. HDLc, HDL cholesterol; LDLc, LDL cholesterol.